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Treatment with tyrosine kinase inhibitors (TKIs) has drastically improved overall survival (OS) of patients with advanced GIST.
The aim of this study is to evaluate the results of treatment with diﬀerent TKIs on advanced GIST and identify prognostic factors
for OS. The medical records of all patients treated at the Department of Oncology, Aarhus University Hospital were retrospectively
reviewed. Between 2001 and 2009, 80 patients with advanced GIST were treated with imatinib as ﬁrst-line therapy. The median
OS was 44 months (95% CI 31–56), and the 5-year OS was 40%. Since 2005, 32 patients were treated with sunitinib as 2nd-line
therapy. The median time to progression was 9 months (95% CI: 3–13 months), and the 3-year OS was 30%. The data illustrate
that data from large multicenter studies are reproducible in a single sarcoma centre. This retrospective study pointed to low serum
sodium at the start of imatinib as a possible prognostic factor aﬀecting OS.
1.Introduction
Gastrointestinal stromal tumour (GIST) is an uncommon
malignancywithanestimatedannualincidenceof14/million
meaning that 50–60 new cases are diagnosed in Denmark
each year. GIST often occurs in the 6th and 7th decade
[1]. Surgery is the standard treatment of primary GIST but
not always curative as approximately 30–50% of all radically
operated patients experience a relapse [2–4].
Insights into the role of Kit signal transduction in the
development of GIST (a gain of function mutation in KIT
and PDGEF genes) has lead to a reliable phenotypic marker
for GIST, the CD117 antigen [5].
The KIT gene encodes a tyrosine kinase which is
inhibited by targeted drugs such as imatinib. Since the ap-
proval in 2001, imatinib has become the recommended
1st-line treatment of unresectable and/or metastatic GIST,
and imatinib has dramatically improved the overall survival
(OS) for this group of patients [6–9].
Poor performance status, high neutrophil count, low
haemoglobin level, male sex, low serum albumin, as well
as diﬀerent types of c-Kit mutations have been identiﬁed as
poor prognostic factors for advanced GIST [3, 6, 8, 10, 11].
Data on the treatment of GIST patients with tyrosine
kinase inhibitors (TKIs) are mainly gathered from large
randomised clinical trials in which patients are selected
accordingtostrictinclusioncriteria.Reportsfromindividual
departmentsontheresponseratesandtoxicitiesencountered
in nonselected patients in routine practice are important in
ordertoevaluatewhetherdatafromlargemulticenterstudies
can be generalised to individual sarcoma centres.2 ISRN Oncology
2. Patientsand Methods
2.1. Patients. All patients with unresectable or metastatic
pathologically conﬁrmed CD117 positive GIST treated at
the Department of Oncology, Aarhus University Hospital in
the period 2001 to 2009 were individually evaluated. Patient
data, tumour characteristic, and treatment modalities were
reviewed retrospectively by systematically reviewing patient’s
medical records, pathology, and computerized tomography
descriptions. The data were collected in a specially designed
case report forms, and analyses were done using SPSS
statistical package (version 18).
2.2.Treatment. Asmutationalanalysiswasnotroutinelyper-
formed, the initial dose of imatinib was left to the doctor’s
decision. Standard practice was imatinib mesylate (Glivec,
Novartis, Switzerland) at an initial dose of 400mg per day
until progression or unacceptable toxicity was observed. In
case of progression according to RECIST criteria [12], the
dose of imatinib was increased to 800mg per day until
progression or unacceptable toxicity. In the year 2005, su-
nitinib was introduced as second-line treatment. The initial
practice was to give 50mg daily for 4 weeks followed by 2
weeks of rest. Later this was changed to a dose of 37.5mg
daily without interruption. Since January 2009 patients
progressing during sunitinib were oﬀered nilotinib 400mg ×
2 daily as 3rd-line treatment. In case of radiological veriﬁed
local progression, local treatment with surgery, RFA, or
stereotactic radiotherapy was performed if feasible and TKI
treatment continued without modiﬁcation. Clinical beneﬁt
was deﬁned as complete response (CR), partial response
(PR), and stable disease (NC) at the ﬁrst evaluation after
initiating the treatment. Palliative radiotherapy was used in
12% of the patients in this study and 6% received palliative
chemotherapy after treatment failure with TKI treatment.
2.3.MedicalExaminationandFollowup. Beforestartofimat-
inib treatment the histological diagnosis was conﬁrmed by a
specialized pathologist. The patients underwent physical ex-
amination,evaluationofperformancestatus,haematological
test, and medical history. Computerized tomography with
contrast served as the method of choice for baseline and
response evaluation. Response evaluation was documented
accordingtotheRECISTcriteria.Afterthestartoftreatment,
the patients were seen on day 14 and 28 to evaluate toxicity.
If no toxicity was observed, patients were controlled every
3 months in the ﬁrst 3 years and every 4 months thereafter.
Toxicity grade 3 or 4 (CTC version 3) lead to dose reduction.
2.4. Blood Analysis. All blood samples were analysed as part
of a routine laboratory procedure before start of treatment.
For the statistical analysis hyponatraemia was deﬁned as
a plasma sodium level <135mmol/L, leukocytosis as white
blood cell count >10 × 109/L, elevated neutrophiles as cell
count >7 ×109/L,andhaemoglobinwasdeﬁnedaslowwhen
<7.4mmol/L.
Table 1: Patient and treatment characteristics.
Imatinib
n = 80 (%)
Sunitinib
n = 32 (%)
Sex
Male 51 (64) 10 (31)
Female 29 (36) 22 (69)
Age, years
Median (years) 63 61
Range 30–87 40–85
Performance status
0 54 (68) 24 (75)
1 18 (22) 6 (19)
2 7( 9 ) 1( 3 )
3 1( 1 ) 1( 3 )
Concomitant disease
No 45 (56) 21 (66)
Yes 35 (44) 11 (34)
Prior malignancy
No 72 (90) 28 (88)
Yes 8 (10) 4 (12)
Primary treatment
Surgery 49 (61) 22 (69)
No prior surgery 31 (39) 10 (31)
Start dose of imatinib/sunitinib
800mg/50mg 10 (13) 10 (31)
400mg/37,5mg 69 (86) 19 (60)
200mg/25mg 1( 1 ) 3( 9 )
Permanent reduction of start dose
No 61 (76) 25 (78)
Yes 19 (24) 7 (22)
Reason for reduction of start dose
Haematological 2 (11)
Musculoskeletal 2 (11) 3 (43)
Multisystem 1( 5 )
Dermatological 7 (37) 3 (43)
Gastrointestinal 6 (31)
Other 1 (5) 1 (14)
Response(a)
CR 3( 4 )
PR 47 (59) 13 (41)
SD 16 (20) 13 (41)
PD 13 (16) 3( 9 )
Death before evaluation 1( 1 ) 3( 9 )
Progression(b)
No 26 (33) 8 (25)
Yes 52 (65) 19 (59)
Not evaluable 2 (2) 5 (16)ISRN Oncology 3
Table 1: Continued.
Imatinib
n = 80 (%)
Sunitinib
n = 32 (%)
Local treatment
No 40 (77) 17 (89)
Yes 12 (23) 2 (11)
(a)Best response at any time during treatment. CR: complete response, PR:
partial response, SD: stable disease, PD: progression of disease.
(b)Progression at the time of evaluation.
2.5. Statistical Analysis. The primary end points in this
study were overall survival (OS) and time to progression
(TTP). TTP was deﬁned as the period from the beginning
oftreatmenttoradiologicalveriﬁedprogressionandOSfrom
the beginning of treatment to the last day of follow-up or
death(ofanycause).Thefollowingpotentialprognosticvari-
ables were investigated for overall survival; sex, performance
status (sore 0v 1–3), concomitant diseases, and categories
of the following baseline laboratory values: neutrophils,
haemoglobin, lactate dehydrogenase, and sodium. For the
prognostic factors evaluated each potential candidate was
initiallyassessedbyunivariateanalysis.Factorsfoundtohave
most impact were included in a multivariate Cox regression
model. For Cox multivariate model all variables were
categorised for haemoglobin into high and low, performance
status into good (PS0) and less (PS 1–3), and serum sodium
into high and low as previously deﬁned. A P value below
0.05 was considered as statistically signiﬁcant. Kaplan-Meier
method was used to evaluate the OS and TTP.
3. Results
3.1. Patient Characteristics. Eighty patients were included
in this study. The characteristics of the patients are shown
in Table 1. 51 males and 29 females were included. The
median age was 63 years (range 30–87 years). A history of
prior cancer was found in 8 patients; 2 patients were for-
merly diagnosed with breast cancer, 1 with prostate cancer,
2 with bladder cancer, 1 T-lymphoblastic lymphoma, 1 with
malignant melanoma, and one patient with testicular cancer.
Ninety percent of the patients were considered in good per-
formance status at the time of referral but 35 patients (44%)
had concomitant diseases. The most common concomitant
disease was hypertension (18%). Other concomitant diseases
were diabetes, chronic obstructive respiratory disorders, or
cardiovascular diseases.
3.2. Tumour Characteristics. The most common anatomic
sites of primary tumours were the stomach 28 (35%) fol-
lowed by the small intestine 21 (26%). Twenty one (26%)
of the patients were considered as having local disease at the
time of referral and 59 (74%) had metastatic disease. Forty
ﬁve (55%) patients had metastasis to one organ, 10 patients
(13%) to 2 organs, and 4 (5%) patients had metastasis to
3 or more organs. The liver was the predominant site for
metastasis.
3.3. Treatment
3.3.1. Response to Imatinib. All 80 patients received imatinib.
Sixty nine (86%) of the patients were initially treated with
400mg per day, while 10 (12%) patients were initially treated
with 800mg per day and 1 patient started with a reduced
dose of 200mg per day. Among patients initially treated
with imatinib 400mg daily 66 (85%) experienced clinical
beneﬁt (CR, PR, or SD) (Table 1). All patients starting with
800mg had initially clinical beneﬁt of the treatment but all
had progressed at the time of evaluation.
At the time of evaluation 52 (65%) patients had pro-
gressedduringimatinibtreatment.Fifteenpatientswithlocal
progression were treated with surgery or radio frequency
ablation (RFA) to eliminate the resistant metastasis. The
median OS was 21 months for patients who could not un-
dergo local treatment (95% CI 4–39 months) compared to
54 months (95% CI 24–84 months) for patients who were
suited for local treatment.
Among the 35 patients increased in imatinib to a dose
of 800mg daily as a consequence of disease progression, 17
(49%) patients experienced clinical beneﬁt (PR + SD).
The median TTP for patients initiated with 400mg of
imatinib was 23 months (95% conﬁdence interval 11–38
months). The median TTP for patients initiated with 800mg
imatinib was 38 months (95% conﬁdence interval 31–45
months). Among the patients increased in imatinib to a
dose of 800mg the median TTP was 3 months (range 2–4
months). At the time of evaluation 21 (26%) patients were
alive and without progression.
Using univariate analysis age, gender, performance sta-
tus, concomitant disease, and diﬀerent serum parameters
such as haemoglobin, neutrophil count, lactate dehydroge-
nase level were not prognostic regarding TTP. Low serum
sodium levels at the beginning of the treatment was associ-
atedwithasigniﬁcantshorterTTPcomparedtopatientswith
normal serum sodium levels (P < 0.05). Low serum sodium
was seen in 14 patients.
3.3.2. Toxicities of Imatinib. Fourteen (20%) patients treated
withimatinib400mgperdayexperiencegrade3or4toxicity
which lead to permanent dose reduction. The toxicities
seen were skin rash (33%) and gastrointestinal side eﬀect
(26%). Fatigue and facial oedema were seen but did not
lead to dose reduction because the side eﬀects were mild or
transient. Among 45 patients who were treated with 800mg
of imatinib, 8 were reduced because of side eﬀects. Overall
4 patients terminated the treatment as a consequence of side
eﬀects and 3 patients refused to continue treatment. Table 1
summarises the toxicity proﬁle of imatinib treatment.
3.3.3. Response to Sunitinib. Thirty two patients received su-
nitinib as 2nd-line treatment after veriﬁed radiological
progression. Nineteen (60%) patients were initiated at a dose
of 37.5mg per oral daily without interruption, 10 (31%)
patients were initiated at a dose of 50mg daily 4 weeks while
3 (9%) patients were initiated with a reduced dose of 25mg
daily. Twenty six (82%) patients experienced clinical beneﬁt4 ISRN Oncology
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Figure 1: Overall survival after imatinib and sunitinib treatment.
(PR or SD). Three patients did not response to the treatment
atanytime, and3patients died beforeevaluationofresponse
(Table 1). Four of 7 patients who did not show any response
to imatinib had clinical beneﬁt of sunitinib treatment. Five
patients experienced local progression; among these, 2 were
treated with surgery. At the time of evaluation 19 patients
had progressed during the treatment.
The median TTP from the beginning of treatment
with sunitinib was 9 months (95% conﬁdence interval
5–13 months). At the time of evaluation 14 (44%) of the
sunitinib-treated patients were still alive and 8 patients
without evidence of progression.
3.3.4. Toxicities of Sunitinib. Seven patients were reduced
in dose as a consequence of side eﬀects, primarily because
of dermatological toxicity and musculoskeletal side eﬀects (6
out of 7 patients). Treatment was terminated for 1 patient
because of extensive mucosal toxicity and declining nutri-
tional status. Two patients refused to continue treatment
with sunitinib.
3.3.5. Overall Survival. The OS from the start of imatinib
(a) and sunitinib (b) are shown in Figure 1,r e s p e c t i v e l y .
The 5-year OS for imatinib was 40% and sunitinib shows
a 2-year OS of 30%. Gender, performance status, con-
comitant diseases, primary tumour site, LDH, haemoglobin,
and neutrophil cell count were not found as prognostic
factors (Table 2). Low serum sodium at the start of imatinib
treatment was associated with reduced OS (Figure 2). Four-
teen patients with low serum sodium at the beginning of
imatinib treatment showed a median OS of 15 months (95%
CI 5–25 months) compared to patient with normal serum
sodium who had a median OS of 61 months (95% CI 47–76
months). The diﬀerence was statistically signiﬁcant both in
an unvariate analysis and in a multivariate model including
haemoglobin and performance status (P < 0.05). Only when
theserumsodiumlevelwasbelownormalrangeitaﬀectsOS.
Whendividingserumsodiumintohighandlowlevelaccord-
ing to the mean value, no signiﬁcant diﬀerence was seen.
4. Discussion
Before the use of imatinib the median OS of unresectable
and metastatic GIST was 5–15 months [4, 13]. After the
introduction of imatinib, a comprehensive meta-analysis
including 1640 patients [8] described a median OS of 57
months. In this paper the median OS was 44 months
(95% CI: 29–57 months). The diﬀerence between these
results could be explained by the fact that this study is a
retrospective clinical study without strict eligibility criteria
such as concomitant disease and previous malignancies. The
median age in our patients’ cohort is slightly older than
in other trials [8, 14, 15]w h i c hm a ya ﬀect OS. It is to be
noted that the survival of the patients with normal serum
sodium is 60 months that is comparable to those reported by
randomised clinical trials.ISRN Oncology 5
Table 2: Univariate and multivariate analysis of potential prognostic factors aﬀecting overall survival.
Univariate analysis Multivariate model
No. of patients No. of events P No. of patients HR P
Gender
Male 51 26
Female 29 16 0.453
PS
05 4 2 6 4 5 1
1–3 26 16 0.207 24 1.2 0.627
Concomitant disease
No 45 23
Yes 32 19 0.353
Site of primary tumour
Small intestine 21 10
Other 59 32 0.213
Serum sodium
Normal 55 22 55 1
Low 14 11 <0.01 14 0.3 0.04
Serum LDH
Normal 44 21
Low 29 16 0.846
Serum Hb
Normal 21 8 20 1
Low 52 29 0.099 49 0.7 0.285
Neutrophil count
Normal 57 29
High 16 8 0.745
Data from the literature describe median TTP during
imatinib treatment in the range 18–37 months [6–8]. Our
result shows a similar median TTP of 27 months (95% con-
ﬁdence interval 17–37 months). Clinical beneﬁt (CR + PR
and SD) has been reported in about 80% of the patients
[6, 7, 14, 16] which also corresponds well with our ﬁndings
with an initial clinical beneﬁt rate of 83%. About 50% of
the patients who progressed during treatment with imatinib
400mg experienced clinical beneﬁt after increasing the dose
of imatinib as previously seen [15]. It is expected that
about 11–14% of all patients will not beneﬁt from imatinib
treatment as seen in this study [14–17]. Thirteen patients
(16%) experienced progression during imatinib 400mg as
best response; among these, 2 patients had clinical beneﬁt
when increasing the dose of imatinib.
Surgical excision of local progression is recommended in
order to eliminate resistant clones and in order to delay the
change or modiﬁcation of imatinib therapy.
In general, imatinib was well tolerated. Twenty two %
of the patients in this study experienced grade 3 or 4
toxicity; the most frequent toxicity seen was dermatological
as expected [15, 17]. Facial oedema was almost always of low
grade and diminished with time, which has also been shown
previously [16].
Since 2005 Sunitinib has been used as 2nd-line treat-
ment in the case of disease progression or intolerance
to imatinib therapy [18]. The largest sunitinib study is a
randomised double-blinded, placebo-controlled, multicen-
tre international trial with 312 patients of which 207 received
sunitinib. This study calculated a median TTP of about 6
months, and 65% of the patients had clinical beneﬁt of the
treatment [19]. Newer studies have shown a median TTP
of 7–9 months and 53–80% of the patients experienced
clinical beneﬁt of the treatment. [20, 21]. In our study the
median TTP was 9 months (95% conﬁdence interval 3–
13 months), and 82% of the patients experienced clinical
beneﬁt of the treatment. The patients in this study were
a little older, but more patients had performance status 0
when compared to the randomised trial. Twenty two % of
the patient experienced toxicity compared to 40% in the
randomised trial.
This study pointed toward low serum natrium as a poor
prognostic factor regarding TTP as well as OS. This observa-
tion could not be explained by concomitant diseases among
the patients with low sodium nor could the performance
status at the start of imatinib treatment. All except one
patient who showed a reduced level of serum sodium had
a normal creatinine level, and there were no difference in
patients’ characteristics between the groups with low and
high sodium (data not shown). No other haematological
or electrolytic parameters were found to be signiﬁcant
regarding their prognostic value.6 ISRN Oncology
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Figure 2: Relation between OS and high/low serum sodium.
Hyponatremia is a common phenomenon in cancer pa-
tients and often associated with poor prognosis. The prog-
nosticvalueofserumsodiumhasbeeninvestigatedforsmall-
cell lung cancer [22], metastatic renal cell carcinoma [23],
hepatocellular carcinoma [24], and gastric cancer [25]. In
the mentioned studies low serum sodium was found to
reduce OS. Furthermore, low serum sodium at the time
of hospitalisation regardless of the cause is associated with
high mortality [26]. Even though this study only includes 14
patients with low serum sodium, hyponatremia signiﬁcantly
reduced the OS compared to patients with normal serum
sodium at the time of initiating treatment. None of our
patients had other causes of hyponatremia such as heart
failure, cirrosis, or nephritic syndrome, and all except one
patient with low serum sodium had normal creatinine in-
dicating normal renal function. This was conﬁrmed by a
multivariate analysis including haemoglobin, performance
status and serum sodium.
Other studies have showed the following adverse prog-
nostic factors: high grade primary tumours, poor perfor-
mance status, high neutrophil counts, low haemoglobin
level, male sex, and GIST from small bowel origin [8, 10].
None of these factors inﬂuenced the OS signiﬁcantly in this
study. The prognostic value of these factors has been tested
regarding time to progression. Because patients in this study
were treated with diﬀerent doses of imatinib and increased
or local treatment was initiated if radiological progression
was observed, we did not look at prognostic factor regarding
initial or late resistance to imatinib. One study has looked for
prognostic factors for overall survival and found that poorer
performance status, male sex, high absolute neutrophil
count, and low albumin were signiﬁcantly associated with
worse overall survival [6]. A good performance status was in
this study deﬁned as PS 0 whereas the study by Blake tested
PS 0 or 1 versus PS 2 or 3. The number of patients in this
study in performance status 2 or more was 8 patients and
no signiﬁcant eﬀect was observed using PS 0 and 1 versus
PS 2 and 3. By testing absolute neutrophil count and by
categorising the count as normal and high, we found no
signiﬁcant (P = 0.291) decrease in OS presumably because
of the low number for patients in this study.
In summary, these data from a single institution conﬁrm
that by following the general recommendations, the overall
excellent clinical outcomes achieved with the use of TKIs
in advanced GIST are as would be expected from clinical
trials. The data pointed toward low serum sodium at the
start of imatinib treatment as an adverse prognostic factor.
However, this statement needs to be conﬁrmed in lager
studies including more patients.
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